Description:

CALGB 40302 TREATMENT AND RESPONSE SUMMARY FORM (SUBSET OF PATIENTS) Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive NCT00390455 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5BC1727-9755-553F-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5BC1727-9755-553F-E034-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 1/8/15
Uploaded on:

January 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

TREATMENT AND RESPONSE SUMMARY FORM Breast Cancer (NCT00390455)

INSTRUCTIONS: Complete and submit this form as required by the protocol. Information in the upper right box must be completed for this form to be accepted. For optimal accuracy use black ink.

Header
Are data amended
Lapatinib/placebo
Dose Modification (Change)
Were there any delays in dose administration
Fluvestrant
Laboratory Values
%
1000/uL
mg/dL
mg/dL
Response Assessment
Has the patient achieved a response?
Has the patient been diagnosed with a new progression (during this reporting period not previously reported?)
Progressive disease documentation (Mark one with an X.)

Similar models